title: ERAP140/Nbla10993 is a novel favorable prognostic indicator for neuroblastoma induced in response to retinoic acid.
abstract: In the present study, we identified a gene termed Nbla10993 whose expression levels are higher in favorable neuroblastomas versus unfavorable ones. Structural analysis showed that Nbla10993 is a novel splicing variant of the ER-associated protein of 140 kDa (ERAP140), which lacks the central acidic as well as the COOH-terminal Cys/His-rich domain. Similarly, ERAP140 was preferentially expressed in favorable neuroblastomas relative to unfavorable ones. During the all-trans-retinoic acid (ATRA)-mediated neuronal differentiation in neuroblastoma-derived RTBM1 cells, the expression levels of ERAP140/Nbla10993 increased at the mRNA level. Consistent with these observations, the luciferase reporter analysis demonstrated that the ERAP140/Nbla10993 promoter responds to ATRA. In addition, the immunoprecipitation/immunoblotting experiments showed that ERAP140 forms a stable complex with RARalpha but not with RXRalpha in cells, suggesting that ERAP140 is involved in RAR-mediated transcriptional regulation. Furthermore, the quantitative real-time PCR analysis using 109 primary neuroblastoma samples demonstrated that the expression levels of ERAP140/Nbla10993 significantly correlate with a better clinical outcome of neuroblastomas. Taken together, our present findings indicate that ERAP140/Nbla10993 plays an important role in the regulation of ATRA-mediated neuronal differentiation, and is a novel member of prognostic indicators for neuroblastoma.
authors.affiliation: Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Arai
authors.forename: Toshinori
authors.initials: T
authors.lastname: Ozaki
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Niizuma
authors.forename: Yohko
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Miki
authors.initials: M
authors.lastname: Ohira
authors.forename: Kunio
authors.initials: K
authors.lastname: Takano
authors.forename: Masahiko
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Akira
authors.initials: A
authors.lastname: Nakagawara
mesh_terms: D000818:Animals; D019556:COS Cells; D002454:Cell Differentiation / Q000187:drug effects*; D002522:Chlorocebus aethiops; D006801:Humans; D047468:Immunoprecipitation; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics* / Q000378:metabolism; D008156:Luciferases / Q000378:metabolism; D009447:Neuroblastoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D056918:Nuclear Receptor Coactivators; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000378:metabolism; D000072482:Retinoic Acid Receptor alpha; D047490:Retinoid X Receptor alpha / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; C455500:NCOA7 protein, human; D056918:Nuclear Receptor Coactivators; C000607071:RARA protein, human; D012333:RNA, Messenger; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D047490:Retinoid X Receptor alpha; D014212:Tretinoin; D008156:Luciferases